Sysmex (OTCMKTS:SSMXY) Stock Price Down 4.6% – Time to Sell?

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) were down 4.6% during trading on Wednesday . The stock traded as low as $8.70 and last traded at $8.70. Approximately 200 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 259,757 shares. The stock had previously closed at $9.12.

Analyst Upgrades and Downgrades

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Sysmex presently has an average rating of “Hold”.

Sysmex Price Performance

The firm has a market capitalization of $5.66 billion, a P/E ratio of 23.66 and a beta of 1.10. The company has a quick ratio of 2.44, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $8.76 and its 200-day moving average is $9.16.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, sell-side analysts predict that Sysmex Corporation ADR will post 0.37 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.